On October 18, JW Therapeutics, a cell therapy company co-founded by Wuxi AppTec and Juno Therapeutics (hereinafter referred to as Juno), passed a listing hearing and will be listed in Hong Kong on November 3. The company’s shareholder lineup is strong. In addition to the founding shareholders, it has also received support from China Resources Capital, Sequoia Capital, Temasek, Arch Venture, CPE, Mirae Asset, etc. This Hong Kong IPO also attracted many domestic and international well-known institutions such as Hillhouse Capital, Rock Springs Capital, Oaktree Capital Management as cornerstone investors.
Cellular immunotherapy is a rare and innovative and ground-breaking treatment method recognized by the global life science industry in recent years, creating a new path for cancer treatment. In 2017, Gilead Sciences announced the acquisition of Kite Pharma for US$11.9 billion in cash. In 2018, Celgene acquired approximately 90% of the outstanding shares of Juno Therapeutics for US$9 billion, which aroused the attention of all parties in the field. On the basis of traditional chemica
On October 18, JW Therapeutics, a cell therapy company co-founded by Wuxi AppTec and Juno Therapeutics (hereinafter referred to as Juno), passed a listing hearing and will be listed in Hong Kong on November 3. The company’s shareholder lineup is strong. In addition to the founding shareholders, it has also received support from China Resources Capital, Sequoia Capital, Temasek, Arch Venture, CPE, Mirae Asset, etc. This Hong Kong IPO also attracted many domestic and international well-known institutions such as Hillhouse Capital, Rock Springs Capital, Oaktree Capital Management as cornerstone investors.
Cellular immunotherapy is a rare and innovative and ground-breaking treatment method recognized by the global life science industry in recent years, creating a new path for cancer treatment. In 2017, Gilead Sciences announced the acquisition of Kite Pharma for US$11.9 billion in cash. In 2018, Celgene acquired approximately 90% of the outstanding shares of Juno Therapeutics for US$9 billion, which aroused the attention of all parties in the field. On the basis of traditional chemical treatments, surgical treatments, and biopharmaceutical target treatments, cellular immunotherapy has brought the hope of survival to countless patients, and it is also considered by many investment institutions, industry analysis institutions and scientists as one of the most important fields of biomedicine in the next 10 years.
At present, three CAR-T products of Novartis’ Kymriah and Gilead’s Yescarta and Tecartus have been approved for the market worldwide. Juno's leading product is expected to be approved by the FDA at the end of 2020, becoming the fourth CD19-targeted product on the market as "best-in-class". This is an autologous CAR T cell therapy, which consists of purified CD8+ and CD4+ T cells in a specific ratio (1:1). It is used to treat the adult patients with relapsed or refractory large B-cell lymphoma that have previously received at least two therapies. The leading product of JW Therapeutics, JWCAR029, was developed on the basis of the introduction of this product technology and has obtained the breakthrough therapy certification of the National Medical Products Administration (NMPA) of China. In addition, JW Therapeutics has also deployed BCMA and other targets, and signed a cooperation agreement with Lyell Immunopharma to develop and commercialize adoptive T cell therapy in China and Southeast Asian countries for the treatment of liver cancer, enriching the company's product pipeline. Relying on the world's leading production and business platform, JW Therapeutics will adopt a model of introduction + independent R&D to continuously provide new treatments for cancer patients in China.
l treatments, surgical treatments, and biopharmaceutical target treatments, cellular immunotherapy has brought the hope of survival to countless patients, and it is also considered by many investment institutions, industry analysis institutions and scientists as one of the most important fields of biomedicine in the next 10 years.
At present, three CAR-T products of Novartis’ Kymriah and Gilead’s Yescarta and Tecartus have been approved for the market worldwide. Juno's leading product is expected to be approved by the FDA at the end of 2020, becoming the fourth CD19-targeted product on the market as "best-in-class". This is an autologous CAR T cell therapy, which consists of purified CD8+ and CD4+ T cells in a specific ratio (1:1). It is used to treat the adult patients with relapsed or refractory large B-cell lymphoma that have previously received at least two therapies. The leading product of JW Therapeutics, JWCAR029, was developed on the basis of the introduction of this product technology and has obtained the breakthrough therapy certification of the National Medical Products Administration (NMPA) of China. In addition, JW Therapeutics has also deployed BCMA and other targets, and signed a cooperation agreement with Lyell Immunopharma to develop and commercialize adoptive T cell therapy in China and Southeast Asian countries for the treatment of liver cancer, enriching the company's product pipeline. Relying on the world's leading production and business platform, JW Therapeutics will adopt a model of introduction + independent R&D to continuously provide new treatments for cancer patients in China.
